Desferrioxamine in chronic progressive multiple sclerosis: a pilot study.
Chronic progressive Multiple Sclerosis is refractory to many conventional treatments. We performed a pilot study testing desferroxamine (DFO) as a candidate in the treatment of chronic progressive Multiple Sclerosis. DFO was given daily by 8 h subcutaneous infusions at a dose of 2 grams daily for 7 days, followed by 1 gram daily for 7 days. Eighteen of 19 individuals completed the full dose of 21 grams. One patient was unable to complete the course due to nausea. No acute deterioration of neurological status was seen during the administration of DFO. No worsening of vision or hearing was noted except that the one patient who was unable to tolerate the medication had a transient reduction in hearing. All patients had a local redness at the injection site. None of the patients had any sudden worsening during or shortly after the treatment. This pilot study suggests that DFO is relatively well tolerated by Multiple Sclerosis patients when given in a short course of therapy.
Lynch
S G
SG
Department of Neurology, University of Kansas Medical Center, Kansas City 66160, USA.
Peters
K
K
LeVine
S M
SM
D000328:Adult; D000931:Antidotes / Q000494:pharmacology*; D002908:Chronic Disease; D003676:Deferoxamine / Q000494:pharmacology*; D005260:Female; D006320:Hearing Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009460:Neurologic Examination; D010865:Pilot Projects
D000931:Antidotes; D003676:Deferoxamine